Materialise NV Q2 2025 Earnings Recap

MTLS Q2 2025 July 25, 2025

Get alerts when MTLS reports next quarter

Materialise NV delivered solid performance in Q2 2025 with notable advancements in its medical sector, despite facing headwinds from geopolitical volatility and macroeconomic uncertainties.

Earnings Per Share Miss

$0.00 vs $0.01 est.

-60.3% surprise

Revenue Beat

76334612 vs 67280000 est.

+13.5% surprise

Market Reaction

1-Day +0.0%

5-Day -1.41%

30-Day -2.91%

See MTLS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved 510(k) U.S. market clearance for personalized alignment in knee surgery, enhancing surgical precision and patient outcomes.
Launched a pilot collaboration with Johnson & Johnson to promote the Mimics thoracic planner in the respiratory market, expanding its medical applications.
Continued strong cash flow positivity, underpinned by R&D investments to drive growth in strategic areas.
Industry-wide investment delays noted due to geopolitical tensions and market uncertainties, impacting near-term growth in Software and Manufacturing segments.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MTLS on AllInvestView.

Next Q3 2025